Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.68 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.47 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.45 |
| ▸ | CTSA | P10619 | 1/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.43 |
| ▸ | MMP12 | P39900 | 1/20 | 0.43 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22630849 | 0.84 | PLA2G10 (0.53) | L3MBTL1TRPM8CTSAEPHX1MMP12 | |
| SCHEMBL12895166 | 0.84 | PLA2G10 (0.53) | L3MBTL1TRPM8CTSAEPHX1MMP12 | |
| SCHEMBL17761208 | 0.84 | PLA2G10 (0.53) | L3MBTL1TRPM8CTSAEPHX1MMP12 | |
| SCHEMBL22643601 | 0.82 | L3MBTL1 (0.49) | L3MBTL1TRPM8CTSAEPHX1MMP12 | |
| SCHEMBL12895269 | 0.82 | L3MBTL1 (0.47) | L3MBTL1SCN9AEPHX1MMP12 | |
| SCHEMBL3405700 | 0.82 | PNMT (0.59) | L3MBTL1TRPM8SCN9A | |
| SCHEMBL3443105 | 0.81 | L3MBTL1 (1.00) | L3MBTL1TRPM8 | |
| SCHEMBL27649238 | 0.79 | TRPM8 (0.49) | L3MBTL1TRPM8EPHX1GPR139 | |
| SCHEMBL1419364 | 0.78 | PNMT (0.67) | L3MBTL1TRPM8EPHX1 | |
| SCHEMBL20764626 | 0.77 | KMT2A (0.61) | TRPM8CTSAEPHX1MMP12GPR139 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210130285-A1 | NOVEL COMPOUNDS ADVANTAGEOUS IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS | AURIMMED PHARMA, INC. | 2021-05-06 | — | — | US | disclosed |
| US-10793515-B2 | Compounds advantageous in the treatment of central nervous system diseases and disorders | AURIMMED PHARMA, INC. (US) | 2020-10-06 | — | — | US | disclosed |
| US-20110046128-A1 | NOVEL COMPOUNDS ADVANTAGEOUS IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS | AURIMMED PHARMA, INC. (US) | 2011-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210130285-A1 | NOVEL COMPOUNDS ADVANTAGEOUS IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS | SMN1; SMN2, HDAC6, HDAC3 | L3MBTL1 1023/4885TRPM8 409/4885SCN9A 531/4885 |
| US-20110046128-A1 | NOVEL COMPOUNDS ADVANTAGEOUS IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS | GAP43, CHRNA10, CHRNA6 | L3MBTL1 2159/4885TRPM8 243/4885SCN9A 338/4885 |
| US-10793515-B2 | Compounds advantageous in the treatment of central nervous system diseases and disorders | SMN1; SMN2, HDAC6, CTSA | L3MBTL1 946/4885TRPM8 368/4885SCN9A 477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.